Mechanism
TB-500 corresponds to the active, actin-binding portion of thymosin beta-4. Its proposed effects are extrapolated largely from research on the full parent protein.
| Mechanism | Detail |
|---|---|
| Actin sequestration | Binds and regulates monomeric G-actin, influencing assembly and turnover of the cytoskeleton that underlies cell movement and structural remodeling. |
| Cell migration | By modulating actin dynamics, Tβ4 promotes directed migration of keratinocytes, endothelial and other repair-associated cells toward sites of injury in preclinical models. |
| Angiogenesis | Parent-protein studies report promotion of new blood-vessel formation, proposed to support tissue perfusion during repair. |
| Anti-inflammatory / remodeling | Preclinical work describes reduced inflammatory signaling and modulation of matrix remodeling, though the specific contribution of the TB-500 fragment is not well characterized in humans. |
Evidence Summary
The mechanistic and repair literature is built mostly on the parent protein thymosin beta-4. Direct evidence for the TB-500 synthetic fragment in humans is absent.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Wound healing & skin repair | Accelerated dermal wound closure in models | Preclinical / parent protein | Robust in animals; TB-500 fragment not separately validated in humans. |
| Cardiac repair | Reduced infarct damage in preclinical models | Preclinical + early human (Tβ4) | Human work is for the full protein (RegeneRx RGN-352), not TB-500. |
| Corneal / ocular repair | Tβ4 ophthalmic studied in dry eye | Human trials (parent protein) | These are Tβ4 trials (RGN-259), not TB-500 injections. |
| Tendon / ligament / muscle | Community’s primary use case | Anecdotal / extrapolated | No RCTs; rationale inferred from Tβ4 biology. |
| Angiogenesis | Blood-vessel formation in preclinical systems | Preclinical | Mechanistically plausible; unproven for TB-500 in humans. |
| Human clinical trials | None for the TB-500 fragment | None | Human clinical evidence belongs to the parent protein Tβ4, not to TB-500. |
Divergence — What This Means
Community treats a preclinical fragment as a proven recovery drug.
TB-500 is discussed as an injury-recovery and tissue-repair peptide, and much of that reputation borrows from the genuine science on thymosin beta-4 — the parent protein, which has real preclinical depth and has reached human trials in ophthalmic and cardiac settings. The synthetic TB-500 fragment sold as a research chemical is not the same molecule studied in those trials.
The honest gap: TB-500 itself has essentially no human randomized trials, no established dose, and no long-term human safety data. What the community reports — faster recovery, reduced injury pain — is anecdotal and extrapolated from parent-protein biology, not demonstrated for the fragment.
The honest gap: TB-500 itself has essentially no human randomized trials, no established dose, and no long-term human safety data. What the community reports — faster recovery, reduced injury pain — is anecdotal and extrapolated from parent-protein biology, not demonstrated for the fragment.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Common community range
2–5 mg
per week, often split
Community frequency
Loading then maintenance
higher weekly for weeks, then reduced
Routes discussed
SC or IM
reconstituted injection
Cycle length discussed
4–6 weeks
loading phase, sometimes maintenance
Figures reflect commonly reported community/forum practice, not clinical dosing. There is no established or approved human dose for TB-500. This is not dosing guidance and not medical advice; TB-500 is sold research-use-only and is not for human use.
Safety Profile
No controlled human safety data exist for TB-500. The following reflects anecdotal community reports and general peptide-injection considerations.
Animal / preclinical — signals observed
Injection-site reactions — redness, swelling, discomfort
Temporary fatigue or lethargy reported by some users
Transient head-rush or lightheadedness reported anecdotally
What is not known (human)
Long-term safety in humans — entirely uncharacterized
Effect on cell proliferation and any theoretical relevance to tumor growth
Interactions with medications or other peptides
Effects of unregulated purity and contaminants in RUO product
Safe dose ceilings and cumulative-exposure risks
Effects listed are community-reported and anecdotal. They are not verified in controlled human studies and should not be read as an established safety profile.
Regulatory Status — Updated July 2026
PCAC recommended TB-500 for the 503A list
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend TB-500 for the 503A bulks list, which would allow it in pharmacy compounding. The vote is advisory only. FDA rulemaking is still pending, and nothing has changed in law — TB-500 remains not FDA approved and is currently sold research-use-only. Track current status →
Where to Source
Source research-grade TB-500
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source TB-500.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein. TB-500 is a shorter synthetic peptide based on Tβ4’s actin-binding region. Most credible human and preclinical research is on the parent protein — not the TB-500 fragment sold as a research chemical.
Not for TB-500 itself. There are no known randomized controlled trials of the synthetic fragment in humans. The human trials people cite used the full thymosin beta-4 protein, a different molecule.
On July 23, 2026, the committee recommended TB-500 for the 503A bulks list by an 8–6–1 vote. This is an advisory recommendation only — not FDA approval, and it does not change the law. FDA rulemaking is still pending. See the regulatory tracker.
Mainly injury recovery and tendon, ligament, and muscle repair. This use is grounded in thymosin beta-4 biology but is not supported by controlled human trials of TB-500; reported benefits are anecdotal.
Compare TB-500